- Được Hội đồng Khoa học kỹ thuật và Hội đồng đạo đức của viện HH TMTW thụng qua.
3. Cần triển khai cỏc xột nghiệm như: chimerism để theo dừi quỏ trỡnh mọc mảnh ghộp Xõy dựng kế hoạch theo dừi sự chuyển đổi nhúm mỏu, giớ
114
TÀI LIỆU THAM KHẢO I. Tiếng Việt I. Tiếng Việt
1. Đỗ Trung Phấn, Nguyễn Quang Tựng và cụng sự (2009), “ Nghiờn cứu ứng dụng qui trỡnh thu gom, xử lý và bảo quản tế bào gốc tạo mỏu sử dụng cho ghộp tủy đồng loại”. Đề tài nghiờn cứu khoa học cấp Bộ, nghiệm thu 12/2009.
2. Nguyễn Quang Tựng, Đỗ Trung Phấn (2006), “Kết quả thu hoạch tế bào CD34 mỏu ngoại vi của người trưởng thành khỏe mạnh sau huy động bằng G-CSF sử dụng cho ghộp tủy đồng loại”. Tạp chớ nghiờn cứu Y học, số 47: 13-19.
3. Quy trỡnh kỹ thuật bệnh viện do Bộ Y tế ban hành (2005), “Chương X: Huyết học- Truyền mỏu”. Tập III, 287- 293.
4. Trần Văn Bộ (1998), “Ghộp tủy xương”. Trong lõm sàng Huyết học. NXB Y học TPHCM.
II. Tiếng Anh:
5. Ades L, Mary J.Y., Robin M, Gluckman E, et al (2004), “Long-term outcome after bone marrow transplantation for severe aplastic anemia”,
Blood; 103:2490-2497.
6. Bacigalupo A, Oneto R, Bruno B et al. (2000), “Current results of bone marrow transplatation in patients with acquired severe aplastic anemia. Report of the European Group for blood and marrow transplatation. On behalf of the Working Party on Severe Aplastic Anemia of the European Group for blood and marrow transplantation”, Acta haematol; 103:19-25.
7. Bacigalupo A(2007). Aplastic Anemia: “Pathogenesis and Treatmant.”
ASH Education Book, 2007: 23-28.
8. Champlin RE, Perez SW, Passweg JR, Klein JP, et al,(2007), “ Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens”. Blood;109:4582-4585.
115
9. Chan K.W, Li C.K, Worth L.L et al., (2001), “A fludarabin-based conditionning regiment for severe aplastic anemia”, Bone marrow transplantion; 27, 125-128.
10. Charles D. Bolan, Susan F. Leitman, Linda M. Griffth, Robert A. Wesley, Jonh A. Barret, and Richard W. Childs (2001), “ Delayed donor red cell chimerism and pure red cell aplastic following major ABO- incompatible nonmyeloablative hematopoietic stem cell transplantation”,
Blood: 98: 1687-1694.
11. Childs R, (2003), “Protocol title: Non-myeloablabtive Allogeneic Peripheral Blood Mobilized hematopoietic Precursor Cell Transplantation for Benign Hematological Disorders and solid Tumors. Americal Society of Hematology Education Program Book”, Hematology: 372-397.
12. Cho BS, KS Eom, YJ Kim, HJ Kim, S Lee, CK Min, SG Cho, WS Min, CW Park, CC Kim and JW Lee (2010), “HLA-mathched sibling transplantation with BM and CD34+-purified PBSCs in adult patients with high-risk severe aplastic anemia to overcome graft rejecttion without an increase in GVHD”, Bone Marrow Transplantation, 45, 1497-1501.(2).
13. George B, Mathews V, Viswabandya A et al.(2007). “ Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia”. Bone Marrow Transplant ;40:13-8
14. Edward C.G.S, and Judith C.W.M, (2005), “Acquired aplastic anaemia, other acquired bone marrow failure disorder and dyserythropoiesis”,
Postgraduate Hematology, Chapter 13(190).
15. Gomez-Almaguer D, Vela-Ojeda J, Jaime-Perez J.C, (2006),
“Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cell and a Fludarabine-based conditionning regiment: The Mexican Experience”, American Journal of Hematology; 81: 157-161.
116
marrow transplantation for severe aplastic anemia”, Blood; 91: 3637- 3645.
17. Judith C.W.M and Young N.S, (2011), “Acquired aplastic anaemia”,
Postgraduate Haematology, Sixth edition: 206-225.
18. Islam MS, Anoop P, Datta P. (2010), “ Implications of CD34+ cell dose on clinical and haematological outcome of allo-SCT for acquired aplastic anaemia”, Bone Marrow Transplantation (2010) 45, 886–894.
19. Kim HJ, Park CY, Park YH, Kim YJ, Kim DW, Min WS and Kim CC, (2003), “Successful allogeneic hematopoietic stem cell transplantation using triple agent immunosuppression in severe aplastic anemia patients”,
Bone marrow Transpaltation, 31,79-86.
20. Kojima S, Matsuyama T, Kato S, Hoshi Y, et al, (2002), “Outcome of 154 patients with severe aplastic anemia”, Blood; 100: 799- 803.
21. Locasciulli A, Oneto R, Bacigalupo A, (2007), “Outcome of patient with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation”, Haematologica; 92: 11-18.
22. Maceijewski J.P and Risitano A.M, (2005), “Aplastic Anemia: Management of Adult Patients”, Hematology : 110- 117.
23. Marshall A. Lichtman (2010), “ Aplastic Anemia: Acquired and Inherited”, Williams Hematology, 8e ,Chapter 34.
24. Mayers G and Maziarz RT., (2010), “Is it time for a chance? The case for early application of unrelated allo-SCT for severe aplastic anemia”, Bone marrow transplantation; 45, 1479-1488.
25. Niparuck P, Ungkanont A, Ativitavas T (2009), “The combined use of Flu/ATG in nonmyeloablative SCT forsevere aplastic anemia with multiple earlier transfusions”, Bone Marrow Transplantation 43, 887–889.
26. Novitzky N, Thomas V, McDonald A, (2009), “Reduced-intensity conditioning for severe aplasia using fludarabine and CY followed by infusion of ex vivo T-cell-depleted grafts leads to excellent engraftment and absence of GVHD”, Bone Marrow Transplantation 43, 779–785.
117
27. Peinemann F, Grouven U, Kroger N, Bartel C, Pittler M.H, Lange S, (2008), “First-line matched related donor Hematopoietic stem cell transplatation compared to immunosuppressive therapy in acquired severe aplastic anemia”, PloS ONE 6(4): e18572, doi:10.1371/journal.pone.0018572.
28. Passweg J., Bacigalupo A., Locasciulli A.(2008), “ HSCT for aplastic anamia in adults” Haematopoietic Stem Cell Transplantation, The EBMT Handbook; Chapter 33: 481-489.
29. Reiner F.Storb, Lucarelli G, McSweeney P.A, and Childs R.W, (2003),
“Hematopoietic Cell Transplantation for Benign Hematological Disorders and Solid Tumors. American Society of Hematology Education Programe Book”, Hematology, 372-397.
30. Robert A. Brodsky. (2009), “ Acquired Aplastic Anemia”, Wintrobe’s Clinical Hematology 12th Edition, Chapter 42.
31. Srinivasan R, Takahashi Y, McCoy J.P, Espinoza-Delgado I, Dorrance C, Igarashi T, Lundqvist A, Barrett A.J, Young N.S, Geller N and Childs R.W (2005) “Over coming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation”, British Journal of Haematology, 133,305-314.
32. Tiercy J.M.(2008), “Immunogenetics of allogeneic HSCT: The role of HLA in HSCT”, Haematopoietic Stem Cell Transplantation, The EBMT Handbook; Chapter 3: 47-65.
33. Young N.S, T.C Rodrigo and Scheinberg P. (2006), “Current concepts in the pathophysiology and treatment of aplastic anemia”, Blood; 108:2509- 2519.
118 PHỤ LỤC 1 PHỤ LỤC 1 BỆNH ÁN NGHIấN CỨU Ghộp đồng loại điều trị bệnh nhõn suy tủy xương I. Phần hành chớnh: 1.1. Người nhận: - Họtờn: - Tuổi: Giới: - Địa chỉ: - Điện thoại liờn hệ: 1.2. Người cho: - Họtờn: - Tuổi: Giới: - Địa chỉ: - Điện thoại liờn hệ:
1.3. Ngày vào viện: Ngày ghộp: Ngày ra viện: Mó hồ sơ: Ngày ra viện: Mó hồ sơ: